Replies to post #3071 on InMed Pharmaceuticals Inc (INM)

[lesgetrich]

In order to monetize bioinformatics, InMed has to show proof that their system works. Producing an effective drug for EB would offer such proof. While the market for EB drugs is relatively small, it is still over $1 billion and could provide millions in revenue to InMed. More than likely, it would be distributed in partnership with a larger drug company and would make InMed a prime acquisition target. INM-750 might also become the first drug to utilize InMed's biosynthesis process for producing cannabinoids, thus proving the efficacy of that technology as well. Consequently, there's a lot riding on the success of InMed's EB drug besides simply the revenues from INM-750 alone.